Mechanism-based pharmacodynamic modeling

Methods in Molecular Biology

Volumn 929, Issue , 2012, Pages 583-600

  Felmlee, Melanie A ^a   Morris, Marilyn E ^a   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Adverse drug effects; Exposure response relationships; Mathematical modeling; Pharmacodynamics; Pharmacokinetics

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BUPRENORPHINE; CAPECITABINE; CITALOPRAM; DAPSONE; DRUG; ENOXAPARIN; ENZYME INHIBITOR; INDISULAM; IRINOTECAN; PARAOXON; PEMETREXED; PRALIDOXIME; TACROLIMUS; VINFLUNINE; WARFARIN;

ADVERSE DRUG REACTION; ARTICLE; BIOASSAY; BLEEDING; BONE MARROW SUPPRESSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXPOSURE; DRUG RECEPTOR BINDING; HUMAN; MATHEMATICAL MODEL; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; QT INTERVAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 84934444096     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-50-2_21     Document Type: Article

References (33)

1. Berger SI, Iyengar R (2011) Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med 3:129-135
2. Levy G (1964) Relationship between elimination rate of drugs and rate of decline of their pharmacologic effects. J Pharm Sci 53:342-343
3. Levy G (1966) Kinetics of pharmacologic effects. Clin Pharmacol Ther 7:362-372
4. Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518
5. Yates FE (1975) On the mathematical modeling of biological systems: a qualified ?pro?. In: Vernberg FJ (ed) Physiological adaptation to the environment. Intext Educational Publishers, New York
6. Wagner JG (1968) Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 20:173-201
7. Friberg LE, Isbister GK, Hackett LP, Duuull SB (2005) The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn 32:571-605
8. Minematsu T, Ohtani H, Yamada Y, Sawada Y, Sato H, Iga T (2001) Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. J Pharmacokinet Pharmacodyn 28:533-554
9. Laizure SC, Parker RB (2009) Pharmacodynamic evaluation of the cardiovascular effects after the coadministration of cocaine and ethanol. Drug Metab Dispos 37:310-314
10. Vage C, Saab N, Woster PM, Svensson CK (1994) Dapsone-induced hematologic toxicity: comparison of the methemoglobinforming ability of hydroxylamine metabolites of dapsone in rat and human blood. Toxicol Appl Pharmacol 129:309-316
11. Furchgott RF (1955) The pharmacology of vascular smooth muscle. Pharmacol Rev 7:183-265
12. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358-371
13. Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M (2007) Pharmacokineticpharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther 321:598-607
14. Stroh M, Addy C,Wu Y, Stoch SA, Pourkavoos N, Groff M, Xu Y, Wagner J, Gottesdiener K, Shadle C, Wang H, Manser K, Winchell GA, Stone JA (2009) Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event. AAPS J 11:99-108
15. Nagashima R, O?Reilly RA, Levy G (1969) Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther 10:22-35
16. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478
17. Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406-419
18. Sharma A, Jusko WJ (1998) Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45:229-239
19. Sharma A, Ebling WF, Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577-1584
20. Woo S, Krzyzanski W, Jusko WJ (2008) Pharmacodynamic model for chemotherapyinduced anemia in rats. Cancer Chemother Pharmacol 62:123-133
21. Sun YN, Jusko WJ (1998) Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87:732-737
22. Mager DE, Jusko WJ (2001) Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210-216
23. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721
24. Zandvliet AS, Schellens JH, Copalu W, Beijnen JH, Huitema AD (2009) Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression. J Pharmacokinet Pharmacodyn 36:39-62
25. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JH, Huitema AD (2008) PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression. Clin Pharmacol Ther 83:829-839
26. Soto E, Staab A, Freiwald M, Munzert G, Fritsch H, Doge C, Troconiz IF (2010) Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. Clin Pharmacol Ther 88:660-667
27. Jusko WJ (1971) Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 60:892-895
28. Fasanmade AA, Jusko WJ (1995) An improved pharmacodynamic model for formation of methemoglobin by antimalarial drugs. Drug Metab Dispos 23:573-576
29. Houze P, Mager DE, Risede P, Baud FJ (2010) Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicity. Toxicol Sci 116:660-672
30. Earp J, Krzyzanski W, Chakraborty A, Zamacona MK, Jusko WJ (2004) Assessment of drug interactions relevant to pharmacodynamic indirect response models. J Pharmacokinet Pharmacodyn 31:345-380
31. Hazra A, Pyszczynski N, DuBois DC, Almon RR, Jusko WJ (2007) Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. J Pharmacokinet Pharmacodyn 34:643-667
32. Barras MA, Duuull SB, Atherton JJ, Green B (2009) Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. Br J Clin Pharmacol 68:700-711
33. Jusko WJ, Ko HC, Ebling WF (1995) Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm 23:5-8